Epidemiology of human African trypanosomiasis

被引:290
|
作者
Franco, Jose R. [1 ]
Simarro, Pere P. [1 ]
Diarra, Abdoulaye [2 ]
Jannin, Jean G. [1 ]
机构
[1] World Hlth Org, Control Neglected Trop Dis, Innovat & Intensified Dis Management, 20 Av Appia, CH-1211 Geneva, Switzerland
[2] World Hlth Org, Inter Country Support Team Cent Africa, Reg Off Africa, Libreville, Gabon
来源
CLINICAL EPIDEMIOLOGY | 2014年 / 6卷
关键词
human African trypanosomiasis; HAT; sleeping sickness; Trypanosoma brucei gambiense; Trypanosoma brucei rhodesiense;
D O I
10.2147/CLEP.S39728
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Human African trypanosomiasis (HAT), or sleeping sickness, is caused by Trypanosoma brucei gambiense, which is a chronic form of the disease present in western and central Africa, and by Trypanosoma brucei rhodesiense, which is an acute disease located in eastern and southern Africa. The rhodesiense form is a zoonosis, with the occasional infection of humans, but in the gambiense form, the human being is regarded as the main reservoir that plays a key role in the transmission cycle of the disease. The gambiense form currently assumes that 98% of the cases are declared; the Democratic Republic of the Congo is the most affected country, with more than 75% of the gambiense cases declared. The epidemiology of the disease is mediated by the interaction of the parasite (trypanosome) with the vectors (tsetse flies), as well as with the human and animal hosts within a particular environment. Related to these interactions, the disease is confined in spatially limited areas called "foci", which are located in Sub-Saharan Africa, mainly in remote rural areas. The risk of contracting HAT is, therefore, determined by the possibility of contact of a human being with an infected tsetse fly. Epidemics of HAT were described at the beginning of the 20th century; intensive activities have been set up to confront the disease, and it was under control in the 1960s, with fewer than 5,000 cases reported in the whole continent. The disease resurged at the end of the 1990s, but renewed efforts from endemic countries, cooperation agencies, and nongovernmental organizations led by the World Health Organization succeeded to raise awareness and resources, while reinforcing national programs, reversing the trend of the cases reported, and bringing the disease under control again. In this context, sustainable elimination of the gambiense HAT, defined as the interruption of the transmission of the disease, was considered as a feasible target for 2030. Since rhodesiense HAT is a zoonosis, where the animal reservoir plays a key role, the interruption of the disease's transmission is not deemed feasible.
引用
收藏
页码:257 / 275
页数:19
相关论文
共 50 条
  • [41] New candidate for human African trypanosomiasis
    不详
    [J]. FUTURE MEDICINAL CHEMISTRY, 2011, 3 (10) : 1240 - 1240
  • [42] Current chemotherapy of human African trypanosomiasis
    Roberto Docampo
    Silvia N. Moreno
    [J]. Parasitology Research, 2003, 90 : S10 - S13
  • [43] Current chemotherapy of human African trypanosomiasis
    Docampo, R
    Moreno, SNJ
    [J]. PARASITOLOGY RESEARCH, 2003, 90 (Suppl 1) : S10 - S13
  • [44] Drug resistance in human African trypanosomiasis
    Barrett, Michael P.
    Vincent, Isabel M.
    Burchmore, Richard J. S.
    Kazibwe, Anne J. N.
    Matovu, Enock
    [J]. FUTURE MICROBIOLOGY, 2011, 6 (09) : 1037 - 1047
  • [45] AFRICAN HUMAN TRYPANOSOMIASIS - IMMUNOENZYMOLOGICAL DIAGNOSIS
    CAILLIEZ, M
    POUPIN, F
    SAVEL, J
    [J]. NOUVELLE PRESSE MEDICALE, 1979, 8 (07): : 522 - 523
  • [46] Eflornithine for the treatment of human African trypanosomiasis
    Burri, C
    Brun, R
    [J]. PARASITOLOGY RESEARCH, 2003, 90 (Suppl 1) : S49 - S52
  • [47] Oral fexinidazole for human African trypanosomiasis
    Chappuis, Francois
    [J]. LANCET, 2018, 391 (10116): : 100 - 102
  • [48] IMMUNOLOGICAL DIAGNOSIS OF HUMAN AFRICAN TRYPANOSOMIASIS
    SAVEL, J
    COULAUD, JP
    [J]. MEDECINE ET MALADIES INFECTIEUSES, 1979, 9 (05): : 293 - 295
  • [49] Human African trypanosomiasis–neurological aspects
    P. G. E. Kennedy
    [J]. Journal of Neurology, 2006, 253 : 411 - 416
  • [50] The human African trypanosomiasis (HAT) platform
    Mbo, F.
    Valverde, O.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 : 239 - 239